Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 973.8 5.8 (0.6%) Market Cap: 107.30 Bil Enterprise Value: 99.48 Bil PE Ratio: 28.77 PB Ratio: 3.98 GF Score: 94/100

Regeneron Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Dec 01, 2020 / 03:30PM GMT
Release Date Price: $514.07 (-0.38%)
Joshua Elliott Schimmer
Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst

All right. Welcome, everyone. This is Josh Schimmer from the Evercore ISI biotech team. Absolutely thrilled to have George Yancopoulos, President and Chief Scientific Officer of Regeneron. We also have Justin Holko, I think -- Vice President of Investor Relations.

I think before we start, Justin has some forward-looking commentary to make for us.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Sure, Josh, and thanks for the invitation to participate in this year's conference. Before we begin, I'd like to remind you that remarks made on the webcast today will include forward-looking statements about Regeneron, including those relating to every great topic that George is going to speak about, mostly science. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot